Research on a rare childhood disorder may provide clues to understanding and treating more common neurodegenerative diseases like Alzheimer’s and Parkinson’s.
The study, published online in Nature Neuroscience, provides new information about A-T disease, in which children have mutations in both of their copies of the ATM gene and cannot make normal ATM protein.
The disorder occurs in an estimated 1 in 40,000 births and leads to problems in movement, coordination, equilibrium, and muscle control as well as a number of other deficiencies outside the nervous system. It leaves children unable to walk by adolescence.
Using mouse and human brain tissue studies, researchers found that without ATM, the levels of a regulatory protein known as EZH2 go up.
Looking through the characteristics of A-T disease in cells in tissue culture and in brain samples from both humans and mice with ATM mutation, they found that the increase in EZH2 was a major contributing factor to the neuromuscular problems caused by A-T.
“We hope that this work will lead to new therapies to prevent symptoms in those with A-T disease,” says Ronald Hart, professor in the department of cell biology and neuroscience at Rutgers.
“But on a larger level, this research provides a strong clue toward understanding more common neurodegenerative disorders that may use similar pathways. It is a theme that has not yet been examined.”
While the EZH2 protein has been shown to help determine whether genes get turned on or off, altering the body’s ability to perform biological functions, necessary for maintaining good health, the new study is the first time this protein—which can cause adverse health effects if there is too much of it—has been looked at in the mature nerve cells of the brain.
By reducing the excess EZH2 protein that accumulated in mice genetically engineered with A-T disease, and creating a better protein balance within the nerve cells, scientists found that mice exhibited improved muscle control, movement, and coordination.
In the study, mutant mice that had A-T disease and increased levels of EZH2 were “cured” when this excess EZH2 protein was reduced. The treated mice were able to stay on a rotating rod without falling off almost as long as the mice that did not have A-T disease.
By contrast, untreated A-T animals lost their balance and fell off the device almost immediately. The mice were also studied in an open area setting. While the treated A-T mice and normal mice explored a wide area of the open field, the A-T mice, with their excess EZH2 protein, were not as adventurous and stayed behind.
The implications of these findings now need to be validated in a clinical setting, researchers say. They have begun working with the A-T Clinical Center at Johns Hopkins University, collecting blood samples from children with the disease as well as their parents who carry the genes in order to reprogram them into stem cells.
This will allow scientists to create human neurons like those in A-T patients and study the mechanisms that lead from ATM mutations to nerve cell disease in more detail.
The hope is that this new information can be used to develop therapeutic drugs that may result in better neuromuscular control and coordination for those with A-T disease.
In addition, the scientists will work to determine whether the EZH2 protein plays a role in other more common neurodegenerative diseases, like Parkinson’s and Alzheimer’s and could offer a target for developing drugs to treat those brain disorders.
“What is interesting about human health and this research in particular is that it illustrates how a disease that is thought of as 100 percent genetic, actually has a component that is sensitive to the environment,” says Karl Herrup, lead author of the study.